John R Teerlink
Overview
Explore the profile of John R Teerlink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
325
Citations
9916
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gallone G, Savoca F, Miccoli D, Bohm M, De Ferrari G, Gottlieb S, et al.
JACC Heart Fail
. 2025 Mar;
PMID: 40088236
Background: Patients with heart failure with reduced ejection fraction (HFrEF) have a heightened stroke risk. However, stroke as an endpoint in heart failure trials remains under-reported. Objectives: The authors sought...
2.
Ferreira J, Vasques-Novoa F, Angermann C, Biegus J, Collins S, Kosiborod M, et al.
Eur J Heart Fail
. 2025 Feb;
PMID: 39980254
Aims: Empagliflozin improves outcomes in acute heart failure (AHF). Patients with AHF and low blood pressure (BP) have poor prognosis. Whether empagliflozin is effective and safe in patients with AHF...
3.
Lala A, Coca S, Feinman J, Hamo C, Fiuzat M, Abraham W, et al.
J Am Coll Cardiol
. 2025 Feb;
85(7):766-781.
PMID: 39971410
Perturbations in kidney function are frequently encountered in heart failure (HF) across its spectrum in both chronic and acute settings with distinct implications for patient management and prognosis. Lack of...
4.
Grand J, Biering-Sorensen T, Teerlink J
JACC Heart Fail
. 2025 Feb;
13(2):253-259.
PMID: 39909638
No abstract available.
5.
Carson P, Teerlink J, Komajda M, Anand I, Packer M, Butler J, et al.
JACC Heart Fail
. 2025 Feb;
PMID: 39895437
Background: There is limited published information on outcome adjudication in heart failure (HF) trials, particularly in heart failure with preserved ejection fraction (HFpEF). Objectives: The study sought to compare investigator...
6.
Voors A, Metra M, Postmus D, Greenberg B, Cotter G, Davison B, et al.
Eur J Heart Fail
. 2024 Dec;
PMID: 39663924
Aims: Serelaxin is recombinant human relaxin-2, a hormone responsible for haemodynamic adaptations and organ protection in pregnancy. In the RELAX-AHF trial, serelaxin demonstrated reductions in cardiac, renal and hepatic damage....
7.
Haghighat L, DeJong C, Teerlink J
Nat Cardiovasc Res
. 2024 Dec;
3(12):1389-1407.
PMID: 39632985
In the past decade, our understanding of heart failure pathophysiology has advanced significantly, resulting in the development of new medications such as angiotensin-neprilysin inhibitors, sodium-glucose cotransporter-2 inhibitors and oral soluble...
8.
Pagnesi M, Staal L, Ter Maaten J, Beldhuis I, Cotter G, Davison B, et al.
JACC Heart Fail
. 2024 Nov;
13(3):414-429.
PMID: 39614837
Background: The prognostic importance of residual congestion after acute heart failure (AHF) hospitalization is still debated. Objectives: The authors aimed to assess the impact of residual congestion in a large...
9.
Zitelny E, Drazner M, Davis J, Reza N, Defilippis E, Khazanie P, et al.
J Card Fail
. 2024 Nov;
PMID: 39577738
No abstract available.
10.
Rosano G, Savarese G, Bohm M, Teerlink J
JACC Heart Fail
. 2024 Nov;
13(1):167-172.
PMID: 39570236
No abstract available.